← Back to Screener
Protalix BioTherapeutics, Inc. Common Stock (PLX)
Price$2.27
Favorite Metrics
Price vs S&P 500 (26W)-10.44%
Price vs S&P 500 (4W)-1.08%
Market Capitalization$184.11M
P/E Ratio (Annual)63.20x
All Metrics
P/CF (Annual)21.36x
Book Value / Share (Quarterly)$0.60
Revenue Growth (3Y)3.45%
Cash Flow / Share (Quarterly)$-0.17
Price vs S&P 500 (YTD)24.75%
Gross Margin (TTM)48.82%
Net Profit Margin (TTM)-12.52%
EPS (TTM)$-0.09
10-Day Avg Trading Volume0.64M
EPS Excl Extra (TTM)$-0.09
Revenue Growth (5Y)-3.46%
EPS (Annual)$-0.08
ROI (Annual)-13.69%
Gross Margin (Annual)48.82%
Net Profit Margin (5Y Avg)-19.52%
Cash / Share (Quarterly)$0.38
P/E Basic Excl Extra (TTM)34.36x
Revenue Growth QoQ (YoY)-49.93%
P/E Normalized (Annual)63.20x
ROA (Last FY)-8.02%
Revenue Growth TTM (YoY)-1.23%
EBITD / Share (TTM)$-0.05
ROE (5Y Avg)70.52%
Operating Margin (TTM)-10.43%
Cash Flow / Share (Annual)$-0.17
P/B Ratio3.82x
P/B Ratio (Quarterly)3.00x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)3.21x
Net Interest Coverage (TTM)-50.93x
ROA (TTM)-8.33%
EPS Growth QoQ (YoY)-26.88%
EV / EBITDA (TTM)21.78x
EPS Incl Extra (Annual)$-0.08
Current Ratio (Annual)2.51x
Quick Ratio (Quarterly)1.54x
3-Month Avg Trading Volume1.08M
52-Week Price Return-10.77%
EV / Free Cash Flow (Annual)23.22x
P/E Incl Extra (TTM)34.36x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.52
P/S Ratio (Annual)3.49x
Asset Turnover (Annual)0.64x
52-Week High$3.19
Operating Margin (5Y Avg)-13.56%
EPS Excl Extra (Annual)$-0.08
CapEx CAGR (5Y)19.94%
26-Week Price Return-1.69%
Quick Ratio (Annual)1.53x
13-Week Price Return12.62%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.51x
Enterprise Value$169.426
Revenue / Share Growth (5Y)-20.82%
Asset Turnover (TTM)0.67x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.15x
Pretax Margin (Annual)-10.63%
Cash / Share (Annual)$0.38
3-Month Return Std Dev72.92%
Gross Margin (5Y Avg)56.89%
Net Income / Employee (TTM)$-0
ROE (Last FY)-13.69%
Net Interest Coverage (Annual)-5.54x
EPS Basic Excl Extra (Annual)$-0.08
P/FCF (TTM)113.16x
Receivables Turnover (TTM)8.98x
EV / Free Cash Flow (TTM)9.77x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.09
Receivables Turnover (Annual)8.98x
ROI (TTM)-13.46%
P/S Ratio (TTM)3.49x
Pretax Margin (5Y Avg)-18.38%
Revenue / Share (Annual)$0.67
Tangible BV / Share (Annual)$-0.20
Forward P/E10.56x
Price vs S&P 500 (52W)-45.86%
P/E Ratio (TTM)34.36x
Year-to-Date Return28.89%
5-Day Price Return1.31%
EPS Normalized (Annual)$-0.08
ROA (5Y Avg)-11.67%
Net Profit Margin (Annual)-12.52%
Month-to-Date Return6.91%
Cash Flow / Share (TTM)$0.18
EBITD / Share (Annual)$-0.05
Operating Margin (Annual)-10.43%
LT Debt / Equity (Annual)6.61x
ROI (5Y Avg)-23.85%
P/E Excl Extra (TTM)34.36x
LT Debt / Equity (Quarterly)0.52x
EPS Basic Excl Extra (TTM)$-0.09
P/TBV (Quarterly)2.73x
P/B Ratio (Annual)3.00x
Inventory Turnover (TTM)1.15x
Pretax Margin (TTM)-10.63%
Book Value / Share (Annual)$0.60
Price vs S&P 500 (13W)9.76%
Beta0.04x
P/FCF (Annual)24.91x
Revenue / Share (TTM)$0.66
ROE (TTM)-13.46%
52-Week Low$1.32
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PLXProtalix BioTherapeutics, Inc. Common Stock | 3.49x | -1.23% | 48.82% | — | $2.27 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Protalix BioTherapeutics develops recombinant therapeutic proteins using its proprietary ProCellEx platform to treat rare lysosomal storage and genetic diseases, including Gaucher disease, Fabry disease, and cystic fibrosis. Revenue comes from product sales in Brazil and a manufacturing supply agreement with Pfizer. The company's pipeline includes ELFABRIO, Uricase, and Long Acting DNase I.